UBS Group
RXRX icon

UBS Group’s Recursion Pharmaceuticals RXRX Stock Holding History

UBS Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.8M Buy
8,947,102
+3,845,865
+75% +$12.8M ﹤0.01% 2170
2026
Q1 		$15.7M Buy
5,101,237
+1,409,215
+38% +$5.45M ﹤0.01% 2857
2025
Q4 		$15.1M Sell
3,692,022
-61,756
-2% -$306K ﹤0.01% 2869
2025
Q3 		$18.3M Sell
3,753,778
-876,812
-19% -$4.6M ﹤0.01% 2671
2025
Q2 		$23.4M Sell
4,630,590
-939,192
-17% -$4.61M ﹤0.01% 2212
2025
Q1 		$29.5M Buy
5,569,782
+2,565,137
+85% +$18.7M 0.01% 1970
2024
Q4 		$20.3M Buy
3,004,645
+2,204,785
+276% +$14.8M ﹤0.01% 2303
2024
Q3 		$5.27M Sell
799,860
-849,190
-51% -$6.09M ﹤0.01% 3016
2024
Q2 		$12.4M Buy
1,649,050
+976,619
+145% +$8.52M ﹤0.01% 2052
2024
Q1 		$6.7M Sell
672,431
-19,480
-3% -$217K ﹤0.01% 2646
2023
Q4 		$6.82M Buy
691,911
+349,232
+102% +$2.49M ﹤0.01% 2439
2023
Q3 		$2.62M Buy
342,679
+173,954
+103% +$1.74M ﹤0.01% 3183
2023
Q2 		$1.26M Sell
168,725
-210
-0.1% -$1.47K ﹤0.01% 4012
2023
Q1 		$1.13M Sell
168,935
-192,960
-53% -$1.53M ﹤0.01% 4004
2022
Q4 		$2.79M Buy
361,895
+343,430
+1,860% +$3.37M ﹤0.01% 3046
2022
Q3 		$196K Buy
18,465
+13,479
+270% +$137K ﹤0.01% 5099
2022
Q2 		$41K Sell
4,986
-1,941
-28% -$13K ﹤0.01% 6076
2022
Q1 		$49K Sell
6,927
-252,295
-97% -$2.68M ﹤0.01% 6523
2021
Q4 		$4.44M Buy
259,222
+188,079
+264% +$3.54M ﹤0.01% 2953
2021
Q3 		$1.64M Buy
71,143
+70,443
+10,063% +$2M ﹤0.01% 3750
2021
Q2 		$26K Buy
+700
New +$20.7K ﹤0.01% 7079

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

UBS Group's RXRX Position: Q2 2026 in Review

UBS Group increased its Recursion Pharmaceuticals (RXRX) stake by 75% in Q2 2026, buying an estimated $12.8M and bringing the position to 8,947,102 shares worth $32.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2170.

UBS Group first reported a position in RXRX in Q2 2021 and has held it in 21 quarters since. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • UBS Group held 8,947,102 shares of Recursion Pharmaceuticals worth $32.8M as of Q2 2026.
  • UBS Group bought 3,845,865 Recursion Pharmaceuticals shares in Q2 2026, an estimated $12.8M.
  • Recursion Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2170 holding.
  • UBS Group first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.